Baseline Characteristics Of Patients With Transthyretin Cardiac Amyloidosis Enrolled In The Patisiran Expanded Access Program

Naveen Saha,Zubair Shah,Mazen A. Hanna,Andriana Nikolova,Colleen Moffitt,Catherine Summers,Kelley Capocelli,Brian M. Drachman

DOI: https://doi.org/10.1016/j.cardfail.2023.10.097

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Transthyretin-mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Treatment for patients with ATTR cardiac amyloidosis is limited, with only the transthyretin (TTR) stabilizer, tafamidis, FDA approved for the treatment of the cardiomyopathy of ATTR amyloidosis in the US. Patisiran, an RNA interference therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy and is being investigated in APOLLO-B for ATTR cardiac amyloidosis. After positive APOLLO-B study results and multiple requests for compassionate use, an expanded access program (EAP) was established and is ongoing in the US to provide patisiran for patients clinically worsening on tafamidis or other disease directed therapy (DDT). Hypothesis To report demographics, baseline characteristics, and safety data for patients enrolled in the APOLLO-B EAP. Methods Patients 18-85 years of age with ATTR cardiac amyloidosis who, at the discretion of the treating physician, have had an inadequate response to or are unable to tolerate tafamidis or other DDT, are eligible for this open-label, multicenter, single-arm program. Patients receive IV patisiran (0.3 mg/kg) every 3 weeks. Baseline demographics and adverse event reports serve as the basis of this . Results As of April 1st, 2023, 22 sites are activated, and 120 patients have received at least one dose of patisiran. Ninety-five percent have a diagnosis of ATTRwt amyloidosis. The majority are Caucasian and male. Six patients with ATTRv amyloidosis are enrolled, with V122I being the most common variant. At diagnosis, 49% of patients are <75 years and 51% are over the age of 75. At enrollment, 88% of patients are NYHA Class II or greater and 30% are Gillmore ATTR amyloidosis disease Stage 2 or 3. Ninety-six percent of patients are on tafamidis, with 70% being treated for less than 2 years. The most frequently reported markers of progression leading to EAP enrollment are increased cardiovascular biomarkers (83%), shortness of breath (68%), and decreased exercise tolerance (64%). More than 80% of the patients had progressed in more than one cardiac manifestation while on tafamidis or other DDT. Other DDT includes green tea and doxycycline/tauroursodeoxycholic acid. Polyneuropathy was reported in 50% of patients with ATTRwt amyloidosis. As of February 28, 2023, the most common adverse events are infusion related reactions (back pain and chest pain/discomfort), insomnia, fatigue, and COVID-19 infection. One patient discontinued due to an infusion related reaction. Conclusions Patients with ATTR cardiac amyloidosis enrolled in the EAP have significant symptom burden despite currently available tafamidis or other DDT. At enrollment, nearly all patients are continuing tafamidis or other DDT. Patisiran, which may provide an additional therapeutic option, has demonstrated an acceptable safety profile among patients with ATTR cardiac amyloidosis in this interim analysis.

cardiac & cardiovascular systems